IGHE and chronic idiopathic urticaria: Approved by several drug administrations for use in asthma and chronic spontaneous urticaria, Omalizumab efficiently neutralizes circulating IgE, and then prevents their binding to FcεRI and lowers their circulating concentrations decreasing FcεRI expression on basophils, mast cells and dendritic cells [66,67,68,69].